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Prerenal acute kidney injury (AKI) is thought to be a
reversible loss of renal function without structural damage.
Although prerenal and intrinsic AKI frequently coexist in
clinical situations, serum creatinine and urine output provide
no information to support their differentiation. Recently
developed biomarkers reflect tubular epithelial injury;
therefore, we evaluated urinary biomarker levels in an adult
mixed intensive care unit (ICU) cohort of patients who had
been clinically evaluated as having prerenal AKI. Urinary
L-type fatty acid–binding protein (L-FABP), neutrophil
gelatinase–associated lipocalin (NGAL), interleukin-18 (IL-18),
N-acetyl-b-D-glucosaminidase (NAG), and albumin in patients
with prerenal AKI showed modest but significantly higher
concentrations than in patients with non-AKI. We also
conducted a proof-of-concept experiment to measure urinary
biomarker excretion in prerenal AKI caused by volume
depletion. Compared with cisplatinum and
ischemia–reperfusion models in mice, volume depletion in
mice caused a modest secretion of L-FABP and NGAL into
urine with more sensitive response of L-FABP than that of
NGAL. Although no histological evidence of structural
damage was identified by light microscopy, partial kidney
hypoxia was found by pimonidazole incorporation in the
volume depletion model. Thus, our study suggests that new
AKI biomarkers can detect mild renal tubular damage in
prerenal acute kidney injury.
Kidney International (2012) 82, 1114–1120; doi:10.1038/ki.2012.266;
published online 1 August 2012
KEYWORDS: acute kidney injury; acute renal failure; L-FABP; NGAL; volume
depletion
In the traditional anatomical flow construct of prerenal,
renal, and postrenal causes, prerenal acute kidney injury
(AKI) and prerenal azotemia have been recognized as distinct
disease conditions from intrinsic AKI and acute tubular
necrosis. However, prerenal AKI frequently coexists with
acute tubular necrosis in clinical situations. Prerenal
azotemia is regarded as a crucial risk factor for ischemic
acute tubular necrosis.1 Acute renal dysfunction indicated by
serum creatinine elevation includes both functional loss and
structural damage to the kidney. Although the Risk-Injury-
Failure-Loss-End stage and Acute Kidney Injury Network
criteria enable standardized AKI diagnosis, these criteria
provide no clue to differentiate the AKI etiology. Recently,
AKI biomarkers have been developed to facilitate early
detection, differential diagnosis, and prognosis.2–5 Among
them, urinary L-type fatty acid–binding protein (L-FABP),
neutrophil gelatinase–associated lipocalin (NGAL), interleu-
kin-18 (IL-18), and kidney injury molecule-1 are regarded as
reflecting tubular epithelial cell injury.6–9 Increased urinary
secretion of these biomarkers can indicate the presence of
tubular damage.
To determine whether AKI patients were suffering from
prerenal causes, two major features have been examined:
fractional excretion of sodium (FENa) and volume respon-
siveness. Although several limitations exist for FENa,
especially in situations of sepsis-associated AKI, AKI with
liver failure or congestive heart failure, chronic kidney
disease, and use of diuretics,10 FENa is the most sensitive
and widely used index among urine indices such as urine-
specific gravity, urine osmolality, and the plasma urea/
creatinine ratio. Volume responsiveness is another feature of
prerenal AKI.11 When AKI is improved promptly by fluid
resuscitation, the patients are categorized as having prerenal
AKI. However, reversibility can only be determined by the
response to fluid over time, indicating the weakness of
retrospective diagnosis. Moreover, fluid resuscitation can
endanger volume-unresponsive AKI patients because fluid
overload worsens AKI outcomes, including mortality.12,13
This study was conducted to evaluate urinary AKI
biomarkers in prerenal AKI patients treated in a mixed
or ig ina l a r t i c l e http://www.kidney-international.org
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medical–surgical intensive care unit (ICU). Considering the
continuum between prerenal AKI and renal AKI,
AKI biomarkers can quantify the burden of structural
injury in prerenal AKI. Recently, Endre et al.14 reported that
urinary biomarkers, including NGAL and IL-18, were
increased in prerenal AKI, which was defined as recovery
within 48 h and FENa o1%. In addition, we conducted a
proof-of-concept experiment with humanized L-FABP
transgenic mice9 to demonstrate that mild elevation of
urinary L-FABP is detectable in prerenal AKI induced by
dehydration.
RESULTS
Clinical study
We analyzed 337 adult patients who had been enrolled
prospectively in our previous study.15 Among them, 129
(38.3%) patients were diagnosed as having AKI within 7 days
after ICU admission. Fifty-one AKI patients showed recovery
within 48 h (transient AKI). No transient AKI patient
was treated by renal replacement therapy within 1 week
after ICU admission. Transient AKI was divided into two
groups according to FENa (o1 or 41%). Another 78
nontransient AKI patients were determined as having renal
AKI (Figure 1). The clinical characteristics and outcomes of
the patients are shown in Table 1. In the transient AKI
groups, AKI severity was significantly milder than in the renal
AKI group. In the renal AKI group, higher 14-day in-hospital
mortality, longer ICU stay, and a higher APACHE II score
were observed than in either the transient AKI or the non-
AKI group. Although the differences were not statistically
significant, the transient AKI groups showed a longer ICU
stay and a higher APACHE II score than did the non-AKI
group. Taken together, the transient AKI groups appeared to
have intermediate severity between the non-AKI and the
renal AKI groups.
The renal AKI group, and also the transient AKI group,
showed significantly higher levels of L-FABP, NGAL, IL-18,
N-acetyl-b-D-glucosaminidase (NAG), and albumin than did
the non-AKI group (Figure 2). The L-FABP and NGAL, in
both absolute concentration and normalized by urinary
creatinine, showed significant differences between non-AKI
and transient AKI, even after adjusting for age and gender
(Supplementary Table S1 online). It is noteworthy that
transient AKI with FENao1% showed high urinary creatinine
levels, whereas transient AKI with FENa 41% showed
significantly lower urinary creatinine levels (Supplementary
Figure S1 online). Consequently, all the urinary biomarkers in
transient AKI with FENa 41% showed significant increases
compared with the non-AKI group, not in absolute concen-
trations but after correction by the urinary creatinine
concentrations (Supplementary Figure S2 online).
Animal study
An animal experiment using human L-FABP transgenic mice
was conducted to provide a proof of concept that increased
urinary L-FABP and NGAL levels were observable in prerenal
AKI. Volume depletion significantly reduced body weight and
increased blood urea nitrogen levels, both of which had
recovered completely at 7 and 14 days (Figure 3). Urinary
L-FABP and NGAL levels were examined in cisplatinum
(CDDP) injection, ischemia–reperfusion (IR), and volume
depletion models (Figure 4). As described in earlier
reports,16,17 CDDP injection at the dose of 20mg/kg and
IR injury by bilateral 30-min renal artery clamp remarkably
induced secretion of L-FABP in urine and increased blood
All AKI
(n = 129)
Non-AKI
(n = 208)
Transient AKI
(n = 51)
Renal AKI
(n = 78)
FENa<1%
(n = 20)
FENa>1%
(n = 31)
Recovery<48h
All patients
(n = 337)
Figure 1 | Study flow diagram. Transient acute kidney injury
(AKI) was defined as recovery within 48 h, while renal AKI was
defined as no recovery within 48 h, irrespective of fractional
excretion of sodium (FENa).
Table 1 | Baseline clinical data and outcomes
Transient AKI
Non-AKI FENa o1% FENa 41% Renal AKI
n=208 n=20 n=31 n=78
Age (years) 66.0 (53.3–74.0) 61.0 (53.5–70.8) 70.0 (49.0–74.0) 65.5 (57.5–74.0)
Male, n (%) 132 (63.5) 14 (70.0) 22 (71.0) 54 (69.2)
AKI severity
Risk, n (%) 14 (70.0) 25 (80.7) 15 (19.2)*
Injury, n (%) 5 (25.0) 6 (19.4) 20 (25.6)
Failure+RRT,
n (%)
1 (5.0) 0 (0.0) 43 (55.1)
Sepsis, n (%) 30 (14.4) 8 (40.0) 4 (12.9) 23 (29.5)*
APACHE II score 10.0 (7.0–13.0) 14.0 (9.3–17.0) 11.0 (8.0–15.0) 17.0
(10.0–23.0)**,***
ICU stay (days) 2.0 (2.0–4.0) 3.0 (2.0–5.8) 3.0 (2.0–5.0) 5.0
(3.0–10.3)**,***
14-day
mortality, n (%)
2 (1.0) 0 (0.0) 1 (3.2) 10 (13.0)*
Abbreviations: AKI, acute kidney injury; FENa, fractional excretion of sodium; ICU,
intensive care unit; RRT, renal replacement therapy.
*Po0.05 by Fisher’s exact test; **Po0.05 vs. non-AKI; ***Po0.05 vs. transient AKI
with FENa41%.
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urea nitrogen levels (mean±s.d.; CDDP at 72 h, 139.1±
21.4mg/dl (n¼ 6); IR at 24 h, 94.1±6.3mg/dl (n¼ 6)).
However, the urinary L-FABP level in volume depletion was
modestly but significantly increased at 24, 48, and 72 h,
whereas blood urea nitrogen showed significant elevation
only at 72 h. The levels of urinary L-FABP in CDDP injection
and IR models were significantly higher than in the volume
depletion model. Urinary NGAL measured at the same time
points also showed significant increases in the volume
depletion model. However, elevation of urinary NGAL in
the volume depletion model was much smaller than in the
CDDP injection and IR models. It is noteworthy that urinary
L-FABP levels in renal AKI (CDDP and IR) were B10–100
times higher than those in prerenal AKI (volume depletion),
whereas urinary NGAL levels in renal AKI were more than
100 times higher than in prerenal AKI. Moreover, no
significant increase was observed when NGAL was normal-
ized by the urinary creatinine concentration in prerenal AKI.
Light microscopy revealed no histological evidence of
tubular injury in the volume depletion model, although
CDDP injection and IR injury induced severe acute tubular
necrosis in kidney tissues (Supplementary Figure S3 online).
Renal hypoxia in the volume depletion model was assessed
using pimonidazole incorporation. Reportedly, cellular
adduction of pimonidazole shows good correlation with
tissue O2 tension.
18 Pimonidazole incorporation was detected
dominantly in the outer stripe of the outer medulla,
especially in proximal tubular epithelial cells, in the volume
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Figure 2 |Urinary biomarkers in non-acute kidney injury (AKI), transient AKI, and renal AKI. Values of five urinary biomarkers
(L-type fatty acid–binding protein (L-FABP; a, b), neutrophil gelatinase–associated lipocalin (NGAL; c, d), interleukin-18 (IL-18; e, f), N-acetyl-b-
D-glucosaminidase (NAG; g, h), and albumin (Alb; i, j)) measured at intensive care unit (ICU) admission are shown for each AKI category (non-
AKI (n¼ 208), transient AKI (n¼ 51), renal AKI (n¼ 78)). Box plots show the median (center line), the 25th and 75th percentiles, and the
range (whiskers). *Po0.0001; wPo0.0005; zPo0.005; yPo0.05 using Steel–Dwass test for multiple comparisons. Cre, creatinine.
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depletion model, although no signal was detected in normal
kidney tissue (Figure 5).
DISCUSSION
The present study evaluated whether new urinary AKI
biomarkers are elevated in prerenal AKI, which was
previously assumed to cause functional loss with no
structural damage. In a cohort of adult mixed ICU patients,
modest but significant increases of urinary L-FABP, NGAL,
IL-18, NAG, and albumin were observed in AKI patients who
had been clinically defined as having prerenal AKI,
FENao1%, and who had recovered within 48 h (transient
AKI) (Figure 2). Moreover, this study revealed that transient
AKI patients with FENa 41% showed lower urinary
creatinine concentration. Therefore, their biomarker levels
were significantly higher than those of non-AKI patients
when normalized by urinary creatinine (Supplementary
Figures S1 and S2 online). These transient AKI patients with
FENa41% might be sufficiently resuscitated or administered
with diuretics at ICU admission (i.e., urinary sample
correction), and their urinary biomarker elevations can be
detected only when corrected by the urinary creatinine
concentration. Recently, Ralib et al.19 reported that normalized
concentration of biomarkers can predict AKI development
after ICU admission. Consistent with this, we also found a
higher frequency of AKI development after ICU admission in
transient AKI patients with FENa 41% (21 of 31, 68%),
whereas 9 of 20 transient AKI patients with FENao1% (45%)
satisfied the AKI diagnosis criteria after ICU admission
(P¼ 0.1073).
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Figure 4 |Urinary L-type fatty acid–binding protein (L-FABP)
and neutrophil gelatinase–associated lipocalin (NGAL) levels
in volume depletion (VD), cisplatinum (CDDP) injection, and
ischemia–reperfusion (IR) injury models. VD induced significant
but modest increases of urinary L-FABP and NGAL compared with
CDDP injection and IR injury models. #Po0.05 vs. 0 h. Cre,
creatinine.
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Figure 3 |Reversible changes of body weight and blood urea
nitrogen (BUN) in volume depletion model. Volume depletion
for 72 h transiently changed body weight (a) and BUN (b), both of
which recovered 7 and 14 days later. Values are mean±s.e.m.
(N¼ 6). #Po0.05 vs. 0 h.
Figure 5 |Renal hypoxia in volume depletion model.
Pimonidazole incorporation following 72-h volume depletion was
observed especially in proximal tubular epithelial cells (a, b),
although no signal was found in the normal kidney (c). Original
magnification,  100 (a, c),  400 (b).
Kidney International (2012) 82, 1114–1120 1117
K Doi et al.: Biomarkers in prerenal acute kidney injury o r ig ina l a r t i c l e
Animal experiments indicated that modest secretion of
L-FABP into urine can be induced by volume depletion, which
was accompanied by partial hypoxia in the kidney (Figures 4
and 5). We demonstrated recently that urinary L-FABP levels in
AKI showed gradual increases with AKI severity. Urinary
L-FABP concentrations in human L-FABP transgenic mice were
elevated even after 5-min IR injury and were correlated
significantly with the ischemia time (5, 15, 30min) and the
histological injury score.17 Results of the present study
demonstrate that simple volume depletion also induced urinary
L-FABP secretion, which was significantly lower than those of
CDDP injection and IR models. Clinical evaluation of our
previous study revealed a gradual increase of urinary L-FABP
along with the AKI severity of the Risk-Injury-Failure-Loss-End
stage.15 The present study found that AKI can be regarded
clinically as prerenal, showing modest but significant increases
of urinary L-FABP compared with non-AKI patients. These
findings support the view that prerenal AKI and renal AKI lie
on a continuum of renal injury and that L-FABP elevation
reflects the severity of structural damage of the kidney.
Results of this study also showed a significant increase of
urinary NGAL in prerenal AKI. In our clinical cohort of an
adult mixed ICU, urinary NGAL in transient AKI patients
showed significant elevation compared with that in non-AKI
patients (Figure 2 and Supplementary Figure S2 online).
A clinical study conducted at an emergency department by
Nickolas et al.20 showed an approximately twofold elevation
of urinary NGAL in prerenal AKI (defined as FENa o1%
and recovered within 3 days) compared with non-AKI
(30.1±90.2 vs. 15.5±15.3 mg per g creatinine). Singer
et al.21 reported that urinary NGAL can distinguish intrinsic
from prerenal AKI. However, 26% of AKI patients were
categorized as having an unclassifiable diagnosis. Their
urinary NGAL values were between prerenal and renal AKI.
Although animal experiments using NGAL reporter mice
showed no increase of NGAL expression in the kidney by
volume depletion,22 we detected a modest but significant
increase of urinary NGAL in the volume depletion model
(Figure 4). It is noteworthy that Paragas et al.22 evaluated
NGAL expression in the reporter mice, not using enzyme-
linked immunosorbent assay but using the luciferase-based
fluorescence imaging technique, whereas we measured urine
NGAL using the enzyme-linked immunosorbent assay
method, which is assumed to be more sensitive than
fluorescence imaging. In addition, the relative increases of
urinary L-FABP and NGAL in prerenal AKI (volume
depletion) compared with renal AKI (CDDP and IR)
differed; urinary L-FABP in prerenal AKI increased by
B10% of that in renal AKI, whereas urinary NGAL in
prerenal AKI was elevated byB1% of that in renal AKI. This
result suggests that L-FABP responds more sensitively to
volume depletion than NGAL.
What stimulates urinary biomarker secretion into urine in
prerenal AKI patients? Reduced renal blood flow is the most
frequent cause of prerenal AKI. Because of the anatomical
structure of the kidney, the outer medullary region can be
exposed easily to hypoxia by low blood flow in the
peritubular capillary. The promoter region of the L-FABP
gene has a hypoxia-responsive element. Therefore, the L-
FABP gene is responsive to hypoxic stress.9 We observed a
mild but significant increase of urinary L-FABP with evidence
of renal hypoxia in volume depletion. These results suggest
that urinary L-FABP in prerenal AKI can be increased by
transient renal hypoxia. We also observed increased urinary
NGAL excretion in the prerenal AKI of both clinical data and
animal experiments. However, the degrees of NGAL eleva-
tions were milder than those of L-FABP as described above.
L-FABP and NGAL are expressed, respectively, in renal
proximal and distal tubular epithelial cells. Hypoxia exam-
ined by hypoxic probe in the animal volume depletion model
was predominantly detected in proximal tubules (Figure 5).
Gobe et al.23 reported the relative resistance to hypoxic injury
of distal tubules. Taken together, the evidence shows that
L-FABP might respond to hypoxia caused by volume
depletion more sensitively than NGAL because of its
regulation (hypoxia-responsive element) and localization
(proximal tubules) of expression in the kidney.
In our adult mixed ICU cohort examined in the present
study, we also found significant elevation of urinary IL-18,
NAG, and albumin concentrations in transient AKI com-
pared with those in non-AKI. Although hypoxic injury
caused by volume depletion or renal hypoperfusion might
have a dominant role in prerenal AKI, prerenal AKI in
clinical situations is assumed to be complicated frequently
with inflammatory conditions such as sepsis. NGAL and
IL-18 can be upregulated by inflammation, whereas urinary
NAG and albumin can be increased in renal tubular injury by
various different etiologies.24,25 Urinary IL-18 in prerenal
AKI was higher than in healthy control subjects in a cross-
sectional study (155±68 vs. 23±9 mg per g creatinine).26
Recently, Endre et al.14 reported that urinary kidney injury
molecule-1, cystatin C, and IL-18 were significantly greater in
prerenal AKI than in non-AKI patients. In the cohorts of
postcardiac surgery AKI, in which renal hypoperfusion is
assumed to be a dominant cause of renal injury, modest
elevation of urinary NAG was observed.27,28 Considering the
continuum between prerenal AKI and renal AKI, these
biomarkers might reflect structural injury in prerenal AKI.
In addition, the duration of injury must be evaluated
because it also has a considerable impact on the biomarker
profile. Endre et al.29 reported that the urinary biomarker
performance was improved by stratifying AKI patients
based on the time after probable renal insult. Although
transient AKI showed recovery within 48 h, information
related to AKI duration before ICU admission is lacking
in this study. Further evaluation is necessary to clarify what
other factors in prerenal AKI affect these urinary biomarker
elevations.
Several limitations might affect the results obtained in this
study. First, we studied adult patients at a single ICU.
Evaluation should be conducted at multicenter ICUs to
confirm our findings. Second, no data related to the usage of
1118 Kidney International (2012) 82, 1114–1120
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diuretics, which might have a significant impact on FENa,
were available for this study. Actually, we determined
prerenal AKI as FENa o1% and rapid recovery within
48 h. Diuretics can increase FENa by inhibiting sodium
reabsorption. Therefore, low FENa with diuretic usage
indicates that the tubular uptake of sodium is induced
remarkably (i.e., prerenal AKI). Finally, we measured urinary
biomarkers at a single time point. Sequential measurements
should be performed in future studies because they can be
expected to improve the biomarker performance remarkably.
In conclusion, modest increases of urinary AKI biomar-
kers were detected in AKI patients who were regarded
clinically as prerenal. Animal experiments with human
L-FABP transgenic mice indicated that renal hypoxia is
associated with urinary secretion of L-FABP in prerenal AKI.
These data suggest that new AKI biomarkers, especially
L-FABP, can detect mild but significant renal tubular injury
that occurs in prerenal AKI.
MATERIALS AND METHODS
Patients and clinical study protocol
This study analyzed data obtained in a prospective observational
study at a single medical–surgical mixed ICU at the University of
Tokyo Hospital to evaluate the performance of new AKI biomarkers:
urinary L-FABP, NGAL, IL-18, NAG, and albumin.15 The University
of Tokyo Institutional Review Board approved the study
protocol. Informed consent was obtained from each participant or
the participant’s family. Inclusion/exclusion criteria, AKI diagnosis,
data collection, and details of measurements for urinary L-FABP,
NGAL, IL-18, NAG, and albumin were described in an earlier
report.15
Urine and serum sodium and creatinine levels were measured on
admission to the ICU. The FENa was calculated as follows: [U/S]
sodium/[U/S] creatinine  100, where U indicates urine and S
indicates serum. According to a recent report by Endre et al.,14
transient and renal AKI were defined as follows. Recovery of AKI was
determined as reduction of serum creatinine from the peak to less
than 0.3mg/dl above baseline. AKI patients who recovered within
48 h were defined as having transient AKI. Transient AKI was
divided into two groups by FENa (41 or o1%). Renal AKI was
defined as non-transient AKI, i.e., no recovery was observed within
48 h, irrespective of FENa.
Animal experiment protocols and measurements
Volume depletion, CDDP injection, and IR models were used,
respectively, to mimic prerenal (volume depletion) and renal AKI
(CDDP and IR). Male heterozygous human L-FABP transgenic mice
(C57BL/6 background) weighing 25–35 g were provided food and
water ad libitum and were kept in glass-shielded metabolic cages
(Metabolica; Sugiyama-gen Iriki, Tokyo, Japan). Simple volume
depletion was induced by water intake restriction (n¼ 6). The
degree of dehydration was evaluated using body weight measure-
ments recorded every 24 h. CDDP (generously provided by Nippon
Kayaku, Tokyo, Japan) at the dosage of 20mg/kg was administered
by intraperitoneal injection (n¼ 6). An ischemia–reperfusion model
induced by 30-min bilateral renal artery clamp was produced as
described in a previous report (n¼ 6).17,30 Urine and blood samples
were collected at 0, 24, 48, and 72 h after initiation of water
restriction, at 0 and 72 h after CDDP injection, and at 0 and 24 h
after IR injury. Animals were killed at 72 h (volume depletion and
CDDP) and 24 h (IR) for histological analyses.
Blood urea nitrogen and urinary creatinine levels were measured
as described previously.17,31 Urinary human L-FABP and mouse
NGAL were measured using sandwich enzyme–linked immunosorbent
assay kits (CMIC, Tokyo, Japan and BioPorto Diagnositics, Gentofte,
Denmark, respectively). For histological examination, the kidneys were
resected from the mice after perfusion with phosphate-buffered
saline. Paraffin sections (3mm thick) were stained with periodic
acid–Schiff. Evaluation of renal hypoxia by pimonidazole immuno-
histochemistry was conducted as described previously.30,32,33
Statistical analyses
For this study, data were expressed as medians (interquartile range)
and compared using the Wilcoxon rank-sum test or Steel–Dwass test
for individual comparison. Categorical variables were described as
proportions and were compared using Fisher’s exact tests. To adjust
age and gender in comparison of transient AKI with non-AKI, a
likelihood ratio test in a multiple logistic regression model was
performed, where the dependent variable was either non-AKI or
transient AKI. These calculations were carried out using the software
JMP 9.0 (SAS Institute, Cary, NC). The null hypothesis was rejected
for Po0.05.
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SUPPLEMENTARY MATERIAL
Table S1. Adjustment of age and gender by likelihood ratio test in
logistic regression model.
Figure S1. Urinary sodium (A) and creatinine (B) concentrations
measured at intensive care unit (ICU) admission are shown in each
acute kidney injury (AKI) category (non-AKI (n¼ 208), transient AKI þ
fractional excretion of sodium (FENa)o1 (n¼ 20), transient AKI þ
FENa 41 (n¼ 31), renal AKI (n¼ 78)).
Figure S2. Urinary biomarkers measured at intensive care unit (ICU)
admission are shown in each acute kidney injury (AKI) category (non-
AKI (n¼ 208), transient AKI þ fractional excretion of sodium (FENa)o1
(n¼ 20), transient AKI þ FENa 41 (n¼ 31), renal AKI (n¼ 78)).
Figure S3. Renal histology of volume depletion (VD), cisplatinum
(CDDP) injection, and ischemia–reperfusion (IR) injury models.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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